Format

Send to

Choose Destination
Pediatr Int. 2016 May;58(5):347-52. doi: 10.1111/ped.12885. Epub 2016 Mar 17.

Usefulness of two interferon-γ release assays for rheumatic disease.

Author information

1
Department of Pediatrics, Yokohama City University Hospital, Kanagawa, Japan.
2
Department of Pediatrics, Yokohama City University Medical Center, Kanagawa, Japan.
3
Department of Pediatrics, International University of Health and Welfare Atami Hospital, Shizuoka, Japan.

Abstract

BACKGROUND:

The aim of this study was to evaluate the performance of two interferon-γ release assays (IGRA), QuantiFERON-TB Gold In-Tube (QFT-GIT) and T-SPOT.TB, for pediatric patients with rheumatic disease in Japan and to analyze the frequencies of indeterminate test results with these kits.

METHODS:

An IGRA was performed in 108 patients <20 years old in order to exclude tuberculosis infection at the time of first application of or change of biological agents and immunosuppressants in Yokohama City University Hospital.

RESULTS:

None of the 108 patients tested had active tuberculosis during the 50 month observation period. Indeterminate results of QFT-GIT and T-SPOT.TB tests were obtained in 9.9% and in 0% of cases, respectively. Indeterminate results were obtained significantly more frequently in patients on prednisolone >0.5 mg/kg and in patients with active underlying disease. Use of biologicals and other immunosuppressants had no effect on these measurements.

CONCLUSIONS:

IGRA are very useful for excluding tuberculosis infection in patients with rheumatic disease before starting new immunosuppressant therapy. Furthermore, the T-SPOT.TB test was suitable for evaluating latent tuberculosis infection even under immunosuppression, when TB tests are generally hard to perform.

KEYWORDS:

biological; children; immunosuppressant; interferon-γ release assay; tuberculosis

PMID:
26670306
DOI:
10.1111/ped.12885
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center